Teva settles patent litigation with Amicus
by
Contributor since / Followers
Contributor since / Followers
1 month ago
JHVEPhoto/iStock Editorial via Getty Images
- Amicus Therapeutics (NASDAQ:FOLD) has agreed to settle patent litigation it initiated against Teva Pharmaceutical (NYSE:TEVA) over the Israeli drugmaker’s plans to seek approval for a generic version of its best-seller, Galafold.
- In a statement on Thursday, Princeton, New Jersey-based Amicus (NASDAQ:FOLD) said that under the agreement, Teva (NYSE:TEVA) receives a license to market a generic version of Galafold after January 30, 2037. The agreement will end the Hatch-Waxman litigation between the companies subject to regulatory clearance.
- The litigation was related to Teva’s (TEVA) plans to market a Galafold generic before the expiry of Amicus’ (FOLD) patents applicable to the drug, which is indicated in the U.S. for a rare genetic condition known as Fabry disease.
- The licensing agreement is expected to be finalized following a review at the U.S. Federal Trade Commission and the Department of Justice.